{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T05:33:21Z","timestamp":1793338401814,"version":"4.5.0"},"reference-count":102,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010878","name":"Abbvie Biotherapeutics Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010878","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jconrel.2026.115340","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T16:28:21Z","timestamp":1788971301000},"page":"115340","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"PA","title":["Effects of intestinal permeation enhancers on solubilization and epithelial transport of the proteolysis targeting chimera (PROTAC) ARV-471 in rats"],"prefix":"10.1016","volume":"399","author":[{"given":"Janis","family":"Niessen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirko","family":"Koziolek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Borchardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anura S.","family":"Indulkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjam\u00edn J.","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Sj\u00f6blom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikael","family":"Hedeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Lennern\u00e4s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Dahlgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2026.115340_bb0005","article-title":"Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines","volume":"10","author":"Xiao","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2026.115340_bb0010","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.4155\/tde.13.104","article-title":"Basics and recent advances in peptide and protein drug delivery","volume":"4","author":"Bruno","year":"2013","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.jconrel.2026.115340_bb0015","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.chembiol.2017.05.024","article-title":"Targeted protein degradation: from chemical biology to drug discovery","volume":"24","author":"Cromm","year":"2017","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.jconrel.2026.115340_bb0020","article-title":"First PROTAC gains FDA approval, bolstering targeted protein degradation and induced proximity ambitions","author":"Mullard","year":"2026","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2026.115340_bb0025","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1021\/acs.jmedchem.7b01272","article-title":"Protac-induced protein degradation in drug discovery: breaking the rules or just making new ones?","volume":"61","author":"Churcher","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2026.115340_bb0030","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrd.2016.211","article-title":"Induced protein degradation: an emerging drug discovery paradigm","volume":"16","author":"Lai","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2026.115340_bb0035","doi-asserted-by":"crossref","first-page":"D1510","DOI":"10.1093\/nar\/gkae768","article-title":"PROTAC-DB 3.0: an updated database of PROTACs with extended pharmacokinetic parameters","volume":"53","author":"Ge","year":"2025","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jconrel.2026.115340_bb0040","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1039\/D4MD00769G","article-title":"Property-based optimisation of PROTACs","volume":"16","author":"Scott","year":"2024","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.jconrel.2026.115340_bb0045","doi-asserted-by":"crossref","first-page":"123","DOI":"10.4155\/fmc-2021-0208","article-title":"PROTAC cell permeability and oral bioavailability: a journey into uncharted territory","volume":"14","author":"Poongavanam","year":"2022","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.jconrel.2026.115340_bb0050","doi-asserted-by":"crossref","first-page":"13106","DOI":"10.1021\/acs.jmedchem.4c01017","article-title":"Structural and physicochemical features of oral PROTACs","volume":"67","author":"Schade","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2026.115340_bb0055","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.addr.2012.09.019","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"64","author":"Lipinski","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2026.115340_bb0060","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1021\/jm020017n","article-title":"Molecular properties that influence the oral bioavailability of drug candidates","volume":"45","author":"Veber","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2026.115340_bb0065","doi-asserted-by":"crossref","first-page":"10005","DOI":"10.1021\/acs.jmedchem.8b01732","article-title":"Why some targets benefit from beyond rule of five drugs","volume":"62","author":"Egbert","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2026.115340_bb0070","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1021\/acsmedchemlett.3c00231","article-title":"The quest for oral PROTAC drugs: evaluating the weaknesses of the screening pipeline","volume":"14","author":"Apprato","year":"2023","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.jconrel.2026.115340_bb0075","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.drudis.2020.03.012","article-title":"Fundamental aspects of DMPK optimization of targeted protein degraders","volume":"25","author":"Cantrill","year":"2020","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jconrel.2026.115340_bb0080","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1039\/D4MD00854E","article-title":"In vitro and in vivo ADME of heterobifunctional degraders: a tailored approach to optimize DMPK properties of PROTACs\u00a9","volume":"16","author":"Maurer","year":"2025","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.jconrel.2026.115340_bb0085","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/j.drudis.2020.07.013","article-title":"Optimising proteolysis-targeting chimeras (PROTACs) for oral drug delivery: a drug metabolism and pharmacokinetics perspective","volume":"25","author":"Pike","year":"2020","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jconrel.2026.115340_bb0090","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1021\/acsmedchemlett.0c00194","article-title":"Systematic investigation of the permeability of androgen receptor PROTACs","volume":"11","author":"Scott","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.jconrel.2026.115340_bb0095","doi-asserted-by":"crossref","first-page":"16355","DOI":"10.1021\/acs.jmedchem.4c01235","article-title":"Between theory and practice: computational\/experimental integrated approaches to understand the solubility and lipophilicity of PROTACs","volume":"67","author":"Venturi","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2026.115340_bb0100","doi-asserted-by":"crossref","first-page":"13765","DOI":"10.1021\/acs.jmedchem.4c00571","article-title":"High-throughput SFC-MS\/MS method to measure EPSA and predict human permeability","volume":"67","author":"Wang","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2026.115340_bb0105","doi-asserted-by":"crossref","first-page":"9584","DOI":"10.1021\/acs.jmedchem.5c00358","article-title":"In vitro ADME profiling of PROTACs: successes, challenges, and lessons learned from analysis of clinical PROTACs from a diverse physicochemical space","volume":"68","author":"Srivastava","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2026.115340_bb0110","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1053\/j.gastro.2016.07.008","article-title":"Inflammation and the intestinal barrier: leukocyte\u2013epithelial cell interactions, cell junction remodeling, and mucosal repair","volume":"151","author":"Luissint","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jconrel.2026.115340_bb0115","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1080\/00498250701704819","article-title":"Intestinal permeability and its relevance for absorption and elimination","volume":"37","author":"Lennern\u00e4s","year":"2007","journal-title":"Xenobiotica"},{"key":"10.1016\/j.jconrel.2026.115340_bb0120","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0022-5193(81)90306-4","article-title":"Predicted absorption rates with simultaneous bulk fluid flow in the intestinal tract","volume":"89","author":"Amidon","year":"1981","journal-title":"J. Theor. Biol."},{"key":"10.1016\/j.jconrel.2026.115340_bb0125","doi-asserted-by":"crossref","DOI":"10.1038\/s12276-018-0126-x","article-title":"Mechanisms regulating intestinal barrier integrity and its pathological implications","volume":"50","author":"Chelakkot","year":"2018","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.jconrel.2026.115340_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpb.2025.114719","article-title":"A comprehensive mechanistic investigation of factors affecting intestinal absorption and bioavailability of two PROTACs in rats","volume":"211","author":"Niessen","year":"2025","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2026.115340_bb0135","doi-asserted-by":"crossref","DOI":"10.1021\/acs.molpharmaceut.6c00207","article-title":"The in vivo effect of amorphous drug nanoprecipitates on the intestinal absorption of the PROTACs ARV-110 (bavdeglutamide) and ARV-471 (vepdegestrant)","author":"Niessen","year":"2026","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2026.115340_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.123725","article-title":"ASDs of PROTACs: spray-dried solid dispersions as enabling formulations","volume":"650","author":"Hofmann","year":"2024","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2026.115340_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2019.105039","article-title":"BRD4 PROTAC as a novel therapeutic approach for the treatment of vemurafenib resistant melanoma: preformulation studies, formulation development and in vitro evaluation","volume":"138","author":"Rathod","year":"2019","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2026.115340_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2022.103387","article-title":"Drug delivery challenges and formulation aspects of proteolysis targeting chimera (PROTACs)","volume":"28","author":"Saraswat","year":"2023","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jconrel.2026.115340_bb0155","doi-asserted-by":"crossref","first-page":"7052","DOI":"10.1021\/acs.molpharmaceut.5c01107","article-title":"Developing multi-component solid formulation strategies for PROTAC dissolution enhancement","volume":"22","author":"Screen","year":"2025","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2026.115340_bb0160","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.ejpb.2019.07.013","article-title":"Intestinal absorption-modifying excipients: a current update on preclinical in vivo evaluations","volume":"142","author":"Dahlgren","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2026.115340_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.113925","article-title":"Formulation strategies to improve the efficacy of intestinal permeation enhancers","volume":"177","author":"Maher","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2026.115340_bb0170","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-64891-0","article-title":"Permeation enhancer-induced membrane defects assist the oral absorption of peptide drugs","volume":"16","author":"Colston","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2026.115340_bb0175","doi-asserted-by":"crossref","first-page":"929","DOI":"10.3109\/03639049309062992","article-title":"The effects of fatty acids and their derivatives on the intestinal absorption of insulin in rat","volume":"19","author":"Muranushi","year":"1993","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.jconrel.2026.115340_bb0180","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1023\/A:1016289200422","article-title":"The effect of absorption enhancers on the oral absorption of the GP IIB\/IIIA receptor antagonist, DMP 728, in rats and dogs","volume":"12","author":"Burcham","year":"1995","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2026.115340_bb0185","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1080\/02652040110081406","article-title":"The effect of oral absorption enhancers on the in vivo performance of insulin-loaded poly(ethylcyanoacrylate) nanospheres in diabetic rats","volume":"19","author":"Radwan","year":"2002","journal-title":"J. Microencapsul."},{"key":"10.1016\/j.jconrel.2026.115340_bb0190","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1007\/s11095-022-03372-1","article-title":"Identification of a multi-component formulation for intestinal delivery of a GLP-1\/glucagon co-agonist peptide","volume":"39","author":"Tran","year":"2022","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2026.115340_bb0195","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1021\/acs.molpharmaceut.1c00724","article-title":"Impact of intestinal concentration and colloidal structure on the permeation-enhancing efficiency of sodium caprate in the rat","volume":"19","author":"Berg","year":"2022","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2026.115340_bb0200","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3390\/pharmaceutics12020099","article-title":"The in vivo effect of transcellular permeation enhancers on the intestinal permeability of two peptide drugs enalaprilat and hexarelin","volume":"12","author":"Dahlgren","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2026.115340_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.122131","article-title":"Characterization of the physicochemical interactions between exenatide and two intestinal permeation enhancers: sodium caprate (C10) and salcaprozate sodium (SNAC)","volume":"626","author":"Twarog","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2026.115340_bb0210","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1023\/A:1012112219578","article-title":"Mechanism of absorption enhancement in humans after rectal administration of ampicillin in suppositories containing sodium caprate","volume":"14","author":"Lindmark","year":"1997","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2026.115340_bb0215","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1211\/0022357021778772","article-title":"The influence of caprate on rectal absorption of phenoxymethylpenicillin: experience from an in-vivo perfusion in humans","volume":"54","author":"Lennern\u00e4s","year":"2002","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.jconrel.2026.115340_bb0220","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1161\/CIRCULATIONAHA.122.063372","article-title":"Orally bioavailable macrocyclic peptide that inhibits binding of PCSK9 to the low density lipoprotein receptor","volume":"148","author":"Johns","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jconrel.2026.115340_bb0225","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.jacc.2023.02.018","article-title":"Phase 2b randomized trial of the oral PCSK9 inhibitor MK-0616","volume":"81","author":"Ballantyne","year":"2023","journal-title":"JACC"},{"key":"10.1016\/j.jconrel.2026.115340_bb0230","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s40265-021-01499-w","article-title":"A pharmacological and clinical overview of oral semaglutide for the treatment of type 2 diabetes","volume":"81","author":"Andersen","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.jconrel.2026.115340_bb0235","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13346-021-01000-w","article-title":"Development and approval of rybelsus (oral semaglutide): ushering in a new era in peptide delivery","volume":"12","author":"Lewis","year":"2022","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.jconrel.2026.115340_bb0240","doi-asserted-by":"crossref","DOI":"10.3390\/ph15121585","article-title":"Gastrointestinal permeation enhancers for the development of oral peptide pharmaceuticals","volume":"15","author":"Kim","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.jconrel.2026.115340_bb0245","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1177\/1091581809337737","article-title":"Subchronic oral toxicity of salcaprozate sodium (SNAC) in Sprague-Dawley and Wistar rats","volume":"28","author":"Riley","year":"2009","journal-title":"Int. J. Toxicol."},{"key":"10.1016\/j.jconrel.2026.115340_bb0250","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aar7047","article-title":"Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist","volume":"10","author":"Buckley","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2026.115340_bb0255","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1023\/A:1015838508656","article-title":"Relationship between drug absorption enhancing activity and membrane perturbing effects of acylcarnitines","volume":"8","author":"LeCluyse","year":"1991","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2026.115340_bb0260","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0022-3565(25)38218-2","article-title":"In vitro effects of long-chain acylcarnitines on the permeability, transepithelial electrical resistance and morphology of rat colonic mucosa","volume":"265","author":"Lecluyse","year":"1993","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jconrel.2026.115340_bb0265","doi-asserted-by":"crossref","first-page":"162","DOI":"10.2133\/dmpk.DMPK-10-RG-071","article-title":"Absorption enhancement effect of acylcarnitines through changes in tight junction protein in Caco-2 cell monolayers","volume":"26","author":"Doi","year":"2011","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.jconrel.2026.115340_bb0270","series-title":"Oral Salmon Calcitonin Pharmaceutical Products","author":"Stern","year":"1999"},{"key":"10.1016\/j.jconrel.2026.115340_bb0275","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1912770","article-title":"A phase 3 trial of difelikefalin in hemodialysis patients with pruritus","volume":"382","author":"Fishbane","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2026.115340_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.xphs.2025.103851","article-title":"Investigating the effect of permeation enhancers on oral absorption of a BCS IV compound, ombitasvir, utilizing animal models","volume":"114","author":"Indulkar","year":"2025","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2026.115340_bb0285","doi-asserted-by":"crossref","first-page":"35","DOI":"10.5599\/admet.4.1.258","article-title":"Simulated rat intestinal fluid improves oral exposure prediction for poorly soluble compounds over a wide dose range","volume":"4","author":"Berghausen","year":"2016","journal-title":"ADMET DMPK"},{"key":"10.1016\/j.jconrel.2026.115340_bb0290","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1023\/A:1016065715308","article-title":"Comparison between permeability coefficients in rat and human jejunum","volume":"13","author":"Fagerholm","year":"1996","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2026.115340_bb0295","first-page":"1166","article-title":"Numerical convolution\/deconvolution as a tool for correlating in vitro with in vivo drug availability","volume":"44","author":"Langenbucher","year":"1982","journal-title":"Pharm. Ind."},{"key":"10.1016\/j.jconrel.2026.115340_bb0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2024.116348","article-title":"Development and validation of LC-MS\/MS methods for the pharmacokinetic assessment of the PROTACs bavdeglutamide (ARV-110) and vepdegestrant (ARV-471)","volume":"249","author":"Niessen","year":"2024","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jconrel.2026.115340_bb0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103865","article-title":"Early evaluation of opportunities in oral delivery of PROTACs to overcome their molecular challenges","volume":"29","author":"Yang","year":"2024","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jconrel.2026.115340_bb0310","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1021\/acsmedchemlett.0c00265","article-title":"Understanding and improving the membrane permeability of VH032-based PROTACs","volume":"11","author":"Klein","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.jconrel.2026.115340_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinthera.2026.03.005","article-title":"Letter to the editor regarding \u201cthe effect of itraconazole on the pharmacokinetics of vepdegestrant, a PROteolysis TArgeting chimera estrogen receptor degrader, in healthy adult participants\u201d recently published by Tran and colleagues","author":"Niessen","year":"2026","journal-title":"Clin. Ther."},{"key":"10.1016\/j.jconrel.2026.115340_bb0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2020.105509","article-title":"Salcaprozate sodium (SNAC) enhances permeability of octreotide across isolated rat and human intestinal epithelial mucosae in Ussing chambers","volume":"154","author":"Fattah","year":"2020","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2026.115340_bb0325","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s11095-007-9438-6","article-title":"Mechanistic understanding of oral drug absorption enhancement of cromolyn sodium by an amino acid derivative","volume":"25","author":"Alani","year":"2008","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2026.115340_bb0330","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s11095-022-03459-9","article-title":"SNAC for enhanced oral bioavailability: an updated review","volume":"40","author":"Kommineni","year":"2023","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2026.115340_bb0335","doi-asserted-by":"crossref","first-page":"5745","DOI":"10.1021\/acs.langmuir.0c00420","article-title":"Surfactant self-assembling and critical micelle concentration: one approach fits all?","volume":"36","author":"Perinelli","year":"2020","journal-title":"Langmuir"},{"key":"10.1016\/j.jconrel.2026.115340_bb0340","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1021\/acs.molpharmaceut.4c01061","article-title":"Molecular investigation of SNAC as an oral peptide permeation enhancer in lipid membranes via solid-state NMR","volume":"22","author":"Ling","year":"2025","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2026.115340_bb0345","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s11154-022-09735-8","article-title":"A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes","volume":"23","author":"Aroda","year":"2022","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"10.1016\/j.jconrel.2026.115340_bb0350","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1021\/acs.molpharmaceut.2c00124","article-title":"Mechanisms and extent of enhanced passive permeation by colloidal drug particles","volume":"19","author":"Narula","year":"2022","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2026.115340_bb0355","doi-asserted-by":"crossref","DOI":"10.1021\/acs.molpharmaceut.4c00751","article-title":"The particle drifting effect: a combined function of colloidal and drug properties","author":"Yang","year":"2024","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2026.115340_bb0360","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1016\/j.xphs.2019.04.006","article-title":"Effect of amorphous nanoparticle size on bioavailability of anacetrapib in dogs","volume":"108","author":"Kesisoglou","year":"2019","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2026.115340_bb0365","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1021\/acs.molpharmaceut.7b00338","article-title":"Impact of drug-rich colloids of itraconazole and HPMCAS on membrane flux in vitro and oral bioavailability in rats","volume":"14","author":"Stewart","year":"2017","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2026.115340_bb0370","doi-asserted-by":"crossref","DOI":"10.1007\/s11095-025-03947-8","article-title":"Predicting food effect on oral drug absorption for solubility-epithelial membrane permeation-limited cases with bile micelle solubilization","author":"Higashiguchi","year":"2025","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2026.115340_bb0375","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2025.126060","article-title":"The particle drifting effect in vivo: impact of dose and animal species","volume":"683","author":"Sharma","year":"2025","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2026.115340_bb0380","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1194\/jlr.M200137-JLR200","article-title":"Interactions of acyl carnitines with model membranes","volume":"43","author":"Ho","year":"2002","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.jconrel.2026.115340_bb0385","doi-asserted-by":"crossref","DOI":"10.1080\/21688370.2017.1361900","article-title":"Intestinal surfactant permeation enhancers and their interaction with enterocyte cell membranes in a mucosal explant system","volume":"5","author":"Danielsen","year":"2017","journal-title":"Tissue Barriers"},{"key":"10.1016\/j.jconrel.2026.115340_bb0390","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.copbio.2018.03.010","article-title":"Selective permeability of mucus barriers","volume":"52","author":"Witten","year":"2018","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.jconrel.2026.115340_bb0395","article-title":"Engineering nanoparticles to overcome the mucus barrier for drug delivery: design, evaluation and state-of-the-art","volume":"12","author":"Liu","year":"2021","journal-title":"Med. Drug Discov."},{"key":"10.1016\/j.jconrel.2026.115340_bb0400","doi-asserted-by":"crossref","first-page":"974","DOI":"10.3390\/pharmaceutics13070974","article-title":"Dual-acting zeta-potential-changing micelles for optimal mucus diffusion and enhanced cellular uptake after oral delivery","volume":"13","author":"Malkawi","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2026.115340_bb0405","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jcis.2021.01.106","article-title":"Surface adsorption and solution aggregation of a novel lauroyl-l-carnitine surfactant","volume":"591","author":"Liu","year":"2021","journal-title":"J. Colloid Interface Sci."},{"key":"10.1016\/j.jconrel.2026.115340_bb0410","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3390\/pharmaceutics11020078","article-title":"Intestinal permeation enhancers for oral delivery of macromolecules: a comparison between salcaprozate sodium (SNAC) and sodium caprate (C10)","volume":"11","author":"Twarog","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2026.115340_bb0415","doi-asserted-by":"crossref","first-page":"26551","DOI":"10.1039\/C7CP04527A","article-title":"Surface pKa of octanoic, nonanoic, and decanoic fatty acids at the air\u2013water interface: applications to atmospheric aerosol chemistry","volume":"19","author":"Wellen","year":"2017","journal-title":"Phys. Chem. Chem. Phys."},{"key":"10.1016\/j.jconrel.2026.115340_bb0420","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1023\/A:1016216905197","article-title":"Regional rectal perfusion: a new in vivo approach to study rectal drug absorption in man","volume":"12","author":"Lennern\u00e4s","year":"1995","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2026.115340_bb0425","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1136\/gut.24.8.734","article-title":"Determination of acid surface pH in vivo in rat proximal jejunum","volume":"24","author":"Lucas","year":"1983","journal-title":"Gut"},{"key":"10.1016\/j.jconrel.2026.115340_bb0430","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ijpharm.2018.05.029","article-title":"The effects of three absorption-modifying critical excipients on the in vivo intestinal absorption of six model compounds in rats and dogs","volume":"547","author":"Dahlgren","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2026.115340_bb0435","doi-asserted-by":"crossref","first-page":"4252","DOI":"10.1021\/acs.molpharmaceut.7b00279","article-title":"Regional intestinal permeability in rats: a comparison of methods","volume":"14","author":"Roos","year":"2017","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2026.115340_bb0440","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ejpb.2019.07.005","article-title":"Rat intestinal drug permeability: a status report and summary of repeated determinations","volume":"142","author":"Dubbelboer","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2026.115340_bb0445","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15102397","article-title":"Challenges in permeability assessment for oral drug product development","volume":"15","author":"Koziolek","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2026.115340_bb0450","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.1007\/s13346-024-01574-1","article-title":"Characterizing interregional differences in the rheological properties and composition of rat small intestinal mucus","volume":"14","author":"Klitgaard","year":"2024","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.jconrel.2026.115340_bb0455","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1021\/mp100144v","article-title":"Simulating fasted human intestinal fluids: understanding the roles of lecithin and bile acids","volume":"7","author":"S\u00f6derlind","year":"2010","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2026.115340_bb0460","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ejpb.2019.07.012","article-title":"Effects of absorption-modifying excipients on jejunal drug absorption in simulated fasted and fed luminal conditions","volume":"142","author":"Roos","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2026.115340_bb0465","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/S0022-2275(20)38051-2","article-title":"Studies on fat digestion, absorption, and transport in the suckling rat. III. Composition of bile and evidence for enterohepatic circulation of bile salts","volume":"23","author":"Staggers","year":"1982","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.jconrel.2026.115340_bb0470","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1211\/jpp.58.8.0009","article-title":"Characterization of fasted-state human intestinal fluids collected from duodenum and jejunum","volume":"58","author":"Moreno","year":"2006","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.jconrel.2026.115340_bb0475","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1007\/s11095-006-9041-2","article-title":"Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model","volume":"23","author":"Cao","year":"2006","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2026.115340_bb0480","doi-asserted-by":"crossref","first-page":"74","DOI":"10.2337\/cd22-0118","article-title":"Current understanding of sodium N-(8-[2-hydroxylbenzoyl] amino) caprylate (SNAC) as an absorption enhancer: the oral semaglutide experience","volume":"42","author":"Solis-Herrera","year":"2024","journal-title":"Clin. Diabetes"},{"key":"10.1016\/j.jconrel.2026.115340_bb0485","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s12276-025-01635-6","article-title":"Drug-induced gastrointestinal toxicity and barrier integrity: cytoskeleton-mediated impairment in a clinically relevant human intestinal epithelium model","volume":"58","author":"Yu","year":"2026","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.jconrel.2026.115340_bb0490","doi-asserted-by":"crossref","first-page":"28056","DOI":"10.1021\/jacs.5c07977","article-title":"Crystallizing the uncrystallizable: insights from extensive screening of PROTACs","volume":"147","author":"Screen","year":"2025","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jconrel.2026.115340_bb0495","doi-asserted-by":"crossref","first-page":"12639","DOI":"10.1021\/acs.jmedchem.2c00201","article-title":"Designing soluble PROTACs: strategies and preliminary guidelines","volume":"65","author":"Garc\u00eda Jim\u00e9nez","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2026.115340_bb0500","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s11095-025-03870-y","article-title":"Modification of peptide and permeation enhancer in vitro release rates by dispersion with a gel-forming polymer","volume":"42","author":"Bapat","year":"2025","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2026.115340_bb0505","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202500946","article-title":"Permeation enhancer-based ionogel shows remarkable potential for oral insulin delivery","volume":"14","author":"Raptis","year":"2025","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.jconrel.2026.115340_bb0510","article-title":"A self-unfolding polymer foil loaded with a permeation enhancer Ionogel for superior oral peptide delivery","author":"Raptis","year":"2026","journal-title":"Drug Deliv. Transl. Res."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926007443?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926007443?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T05:17:46Z","timestamp":1793337466000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365926007443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":102,"alternative-id":["S0168365926007443"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115340","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of intestinal permeation enhancers on solubilization and epithelial transport of the proteolysis targeting chimera (PROTAC) ARV-471 in rats","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115340","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"115340"}}